BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1131 related articles for article (PubMed ID: 30825132)

  • 21. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
    Incorvaia L; Fanale D; Badalamenti G; Barraco N; Bono M; Corsini LR; Galvano A; Gristina V; Listì A; Vieni S; Gori S; Bazan V; Russo A
    Adv Ther; 2019 Oct; 36(10):2600-2617. PubMed ID: 31432460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
    J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data.
    Boussageon M; Swalduz A; Chouaïd C; Bylicki O
    BioDrugs; 2022 Mar; 36(2):137-151. PubMed ID: 35147894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm.
    Breimer LH; Nousios P; Olsson L; Brunnström H
    Scand J Clin Lab Invest; 2020 Sep; 80(5):360-369. PubMed ID: 32238062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis.
    Tartarone A; Roviello G; Lerose R; Roudi R; Aieta M; Zoppoli P
    Future Oncol; 2019 Jul; 15(20):2423-2433. PubMed ID: 31237152
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Chen R; Hou X; Yang L; Zhao D
    Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
    Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.
    Wu Y; Lin L; Shen Y; Wu H
    Int J Cancer; 2018 Dec; 143(11):3038-3040. PubMed ID: 29987914
    [No Abstract]   [Full Text] [Related]  

  • 31. Nivolumab plus ipilimumab in non-small-cell lung cancer.
    Reck M; Borghaei H; O'Byrne KJ
    Future Oncol; 2019 Jul; 15(19):2287-2302. PubMed ID: 31066582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
    Zhou Y; Chen C; Zhang X; Fu S; Xue C; Ma Y; Fang W; Yang Y; Hou X; Huang Y; Zhao H; Hong S; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):155. PubMed ID: 30577837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
    Remon J; Pardo N; Martinez-Martí A; Cedrés S; Navarro A; Martinez de Castro AM; Felip E
    Lung Cancer; 2017 Apr; 106():70-75. PubMed ID: 28285697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
    Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
    Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer.
    Rebuzzi SE; Leonetti A; Tiseo M; Facchinetti F
    Immunotherapy; 2019 Aug; 11(12):993-1003. PubMed ID: 31319742
    [No Abstract]   [Full Text] [Related]  

  • 38. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
    Samimi M
    Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].
    Lantuejoul S; Adam J; Girard N; Duruisseaux M; Mansuet-Lupo A; Cazes A; Rouquette I; Gibault L; Garcia S; Antoine M; Vignaud JM; Galateau-Sallé F; Sagan C; Badoual C; Penault-Llorca F; Damotte D;
    Ann Pathol; 2018 Apr; 38(2):110-125. PubMed ID: 29571563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.